Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Orion Office REIT Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Orion Office REIT Inc trades at $2.67 (market cap $151.17M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 53.2× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | ONL | |
|---|---|---|
Market Cap | $8.04B | $151.17M |
Sector | Health | Real Estate |
52-Week High | $339.75 | $3.04 |
52-Week Low | $241.71 | $1.93 |
Enterprise Value | $7.85B | $634.82M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
ONL trades at $2.72, down 1.09% today, with a bearish technical signal and negative earnings momentum. The company reported Q1 2026 EPS of -$0.24, missing expectations, while revenue declined to $147.65M in 2025. Despite a low P/B of 0.25, profitability remains weak with a -98.36% net margin. Recent news highlights strategic reviews and portfolio repositioning toward dedicated-use assets.
The outlook is cautious due to persistent losses and declining revenue, though strategic asset sales and debt management provide some stability. Risks include high leverage and office market challenges. Analyst sentiment is mixed with 50% buy ratings. Investment opportunity hinges on successful execution of strategic initiatives amid a difficult operating environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
